Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4177830 | 1.00 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL4161531 | 1.00 | TAS1R3 (0.66) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL13928024 | 0.84 | TAS1R3 (0.81) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL4175750 | 0.84 | TAS1R3 (0.81) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL4175061 | 0.84 | TAS1R3 (0.81) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL24571672 | 0.81 | TAS1R3 (0.56) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL700841 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL702725 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL700840 | 0.79 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 | |
| SCHEMBL20662892 | 0.78 | TAS1R3 (0.89) | TAS1R3TAS1R1TAS1R2PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | DEWIS MARK L | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047379-A1 | Benzamide Compounds Useful as High Potency Sweet Taste Enhancers | TAS2R10, TAS2R50, TAS2R8 | TAS1R3 27/4885TAS1R1 23/4885TAS1R2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.